Galapagos (NASDAQ:GLPG) Sets New 12-Month Low at $31.22

Shares of Galapagos NV (NASDAQ:GLPG) reached a new 52-week low during trading on Wednesday . The company traded as low as $31.22 and last traded at $31.22, with a volume of 17633 shares. The stock had previously closed at $31.65.

Analysts Set New Price Targets

A number of equities analysts recently commented on GLPG shares. StockNews.com cut shares of Galapagos from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. Bank of America reaffirmed an “underperform” rating and set a $31.00 price target (down from $41.00) on shares of Galapagos in a research note on Thursday, March 28th. Finally, Morgan Stanley started coverage on shares of Galapagos in a research note on Thursday, March 7th. They set an “equal weight” rating and a $38.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $34.50.

Galapagos Trading Down 0.9 %

The company has a market capitalization of $2.03 billion, a PE ratio of -13.47 and a beta of 0.24. The firm’s 50-day simple moving average is $35.22 and its 200-day simple moving average is $36.62.

Institutional Investors Weigh In On Galapagos

Several large investors have recently added to or reduced their stakes in GLPG. Segall Bryant & Hamill LLC purchased a new stake in Galapagos in the 1st quarter valued at about $11,568,000. Stonepine Capital Management LLC purchased a new stake in Galapagos in the 4th quarter valued at about $8,647,000. Point72 Asset Management L.P. boosted its position in Galapagos by 23.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 880,668 shares of the biotechnology company’s stock valued at $35,808,000 after buying an additional 165,068 shares during the period. BlackRock Inc. boosted its position in Galapagos by 46.8% in the 1st quarter. BlackRock Inc. now owns 517,611 shares of the biotechnology company’s stock valued at $32,103,000 after buying an additional 164,912 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in Galapagos in the 4th quarter valued at about $5,284,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.